A carregar...
Ibrutinib is not an effective drug in primografts of TCF3-PBX1
AIM: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients with multiple myeloma, non-Hodgkin lymphoma and chronic lymphoblastic leukemia. We previously showed that primary cells of children with TCF3-PBX1 positive B-cell precursor acute lymphoblastic leuke...
Na minha lista:
| Publicado no: | Transl Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Neoplasia Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7306596/ https://ncbi.nlm.nih.gov/pubmed/32563910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2020.100817 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|